#	Pagina
attuale pagina	/open-h2020/projects/197307/index.html

Opendata, web and dolomites

RABIOPRED SIGNED

RABIOPRED - Clinical validation of BIOmarker assay to PREDict treatment response in Rheumatoid Arthritis (RA) patients

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

RABIOPRED project word cloud

Explore the words cloud of the RABIOPRED project. It provides you a very rough idea of what is the project "RABIOPRED" about.

predictive collaborating introduction analytical tcland sustainability care market alpha treatment therapies decision ra ce pharmaceutical strategies clinicians focusses immune companion inhibiting evaluation disorders predict validated rabiopred millions line patients blood medicine companies noninvasive inhibitors assay patented tnf french network initial beforehand agents sme rheumatoid final tests diagnostics innovative ready ivd biomarker arthritis molecular outcomes centers proof validation expression diagnostic clinical biological subsequent multibillion unable personalized sa assays prototype international signature biomarkers expensive 40 performance model mediated commercialization gene registered health

Project "RABIOPRED" data sheet

The following table provides information about the project.

Coordinator	TcLand Expression Organization address address: rue de la Noue Bras de Fer city: NANTES postcode: 44200 website: http://www.tcland-expression.com/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Project website	http://www.rabiopred-project-h2020.eu/
Total cost	4˙995˙250 €
EC max contribution	4˙995˙250 € (100%)
Programme	1. H2020-EU.3.1. (SOCIETAL CHALLENGES - Health, demographic change and well-being) 2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
Code Call	H2020-SMEINST-2-2014
Funding Scheme	SME-2
Starting year	2015
Duration (year-month-day)	from 2015-07-01 to 2018-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	TcLand Expression TcLand Expression Organization address address: rue de la Noue Bras de Fer city: NANTES postcode: 44200 website: http://www.tcland-expression.com/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (NANTES)	coordinator	4˙995˙250.00

Map

Project objective

The aim of the RABIOPRED project is to take the final steps to bring an innovative set of biomarkers that is able to predict response to treatment with TNF-α inhibitors in Rheumatoid Arthritis (RA) to the market and clinical practice.

Millions of RA patients are treated with TNF-α inhibiting agents, currently one of the main second-line treatment strategies for RA. These expensive biological RA therapies represent a multibillion market. However, the TNF-α inhibiting agents are not effective in 30-40% of the patients. Clinicians are currently unable to predict the response to this treatment beforehand. The ability to predict response to treatment would greatly improve clinical decision-making, improve health outcomes for RA patients, and contribute to cost reduction and sustainability of the health care system.

The RABIOPRED assay is based on a novel gene expression signature and a predictive model, that have been identified and developed by TcLand Expression SA and that have been patented. Proof-of-concept has already been obtained for the prototype biomarker assay. The analytical validation and clinical performance evaluation of the RABIOPRED assay in the current project are the final development steps towards market introduction and clinical application. At the end of this 3.5 year project, a validated and CE registered IVD biomarker assay will be available that is ready for clinical application, initial market introduction and further commercialization and implementation.

TcLand Expression SA is a French SME developing biomarkers for personalized medicine and companion diagnostics in immune mediated disorders. TcLand focusses on development and validation of noninvasive multi-gene molecular diagnostic blood tests. TcLand is embedded in an international network of collaborating pharmaceutical companies and clinical centers throughout Europe, facilitating clinical performance evaluation and enhancing subsequent market uptake of novel biomarkers assays.

Deliverables

List of deliverables.
Project website	Websites, patent fillings, videos etc.	2019-05-30 12:47:24

Take a look to the deliverables list in detail: detailed list of RABIOPRED deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RABIOPRED" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RABIOPRED" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.;H2020-EU.2.3.1.)

PREPARE (2016)

Preventing Respiratory Events through Proactive Assessment of Respiratory Effort

SIME-LMT (2015)

Development of a digital diagnostics rapid Lung Maturity Test (LMT) for premature infants, to assist neonatologists in the diagnosis of Respiratory Distress Syndrome at birth